Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

BTG & The Generics Group combine key patents & grant licence for development of new bio-chip technology

BTG : 29 January, 2003  (Company News)
BTG, the global technology commercialisation company, announced today that it has worked with The Generics Group, the technology consulting, development and investment organisation, to create the potential for a new bio-chip technology. Together they are licensing a patent portfolio in electronics and the life sciences to Aura Oncology Systems Inc., which could lead to a bio-chip technology that could assist in the diagnosis of cancer and the development of new oncology drugs.
BTG, the global technology commercialisation company, announced today that it has worked with The Generics Group, the technology consulting, development and investment organisation, to create the potential for a new bio-chip technology. Together they are licensing a patent portfolio in electronics and the life sciences to Aura Oncology Systems Inc., which could lead to a bio-chip technology that could assist in the diagnosis of cancer and the development of new oncology drugs.

The technologies, which are based on 'dielectrophoresis', were developed by Professor Ronald Pethig and colleagues at the University College Bangor, North Wales, UK, in collaboration with Aura Oncology. These technologies have a potential role in the fast-developing field of cell biology, relating to the development of treatments for cancer. They work by marrying microelectronics and biology to provide a next generation of processing and diagnostic tools for research and clinical applications. Bio-separation devices made of microelectronic arrays controlled by AC (alternating current) voltages, are used to identify and separate of biological particles, such as cells, viruses and protein molecules.

Anthony Lando, Executive VP and Divisional Director of BTG said: 'By working with The Generics Group, we were able to combine our own patents in electronics and medical science with those of Professor Pethig, creating a unique portfolio. This platform allows Aura Oncology to accelerate its research into the use of bio-chip technology in the fields of drug discovery and cell biology.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo